Evaluation of Anticancer Activity of Pomegranate Punica granatum on human liver cancer cell line / (Record no. 176947)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 08579namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20251223105413.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251222s2024 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99407 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 616.99407 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.12.21.M.Sc.2025.Me.E |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Medhat Ali El-Sakka, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Evaluation of Anticancer Activity of Pomegranate Punica granatum on human liver cancer cell line / |
| Statement of responsibility, etc. | by Medhat Ali El-Sakka ; Supervision Prof. Dr. Aliaa Mahmoud Issa ,Dr. Wesam Taha Basal, Dr. Neima koutb El-Senousy. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | تقييم النشاط المضاد للسرطان لنبات الرمانبيونكا جراناتم على خطوط خلايا الكبد السرطانية للإنسان |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 99 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc)-Cairo University, 2024. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 56-99. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Liver cancer is the third most common cause of cancer-related mortality. Over <br/>80% of liver cancer patients are diagnosed with hepatocellular carcinoma (HCC) <br/>which is resistant to most conventional chemotherapeutic agents. Moreover, the <br/>use of these agents is typically associated with side effects that lead to the <br/>destruction of normal tissues. Therefore, finding a therapeutic agent that is <br/>selective, non-toxic to normal cells, and does not develop resistance or <br/>unpleasant side effects became the most challenging aspect in cancer therapy. <br/>The present study investigates the potential selective antitumorigenic effects of <br/>pomegranate peel extract by studying the effect of the extract on cell viability, <br/>DNA fragmentation, cell cycle arrest, and the expression of cancer related genes <br/>in human hepatocellular carcinoma cell line (HepG2), and normal human <br/>hepatocyte cell line (THLE2). The previous parameters were evaluated using <br/>MTT, comet assay, flow cytometry and real time PCR, respectively. Inhibition <br/>concentrations for 50% of the cells (IC50) were determined for both types of cell <br/>lines using MTT test. The concentrations equivalent to (¼ and ½) of IC50 for the <br/>HepG2 were used for the treatment of both cell lines in all the following <br/>investigations. In comet assay both pomegranate peel extract concentrations <br/>showed significant damage (P ≤ 0.05) in DNA of HepG2 cell line as indicated by <br/>the increase in tail length, tail DNA% and tail moment as compared to the <br/>untreated control cells. On the other hand, no significant change in DNA <br/>integrity was recorded between treated and untreated THLE2 cells. Same <br/>observations were recorded in flow cytometry results. It was found that both <br/>concentrations of the peel extract caused cell cycle arrest at G0/G1 and S phases <br/>in HepG2 but not THLE2.Quantitative real time PCR showed that <br/>both concentrations of peel extract significantly decreased the expression levels <br/>of cyclooxygenase-2, which participates in tumor growth by immune invasion <br/>and resistance to apoptosis, in HepG2 cells, and to a lesser extent in THLE2 <br/>cells. The expression levels of cell cycle genes, CyclinB1 and Cyclin dependent <br/>kinase1, were significantly decreased in HepG2 cells, while in THLE2, only <br/>Cdk1 showed a significant decrease, but not CyclinB1. In case of the apoptosis <br/>related genes, the Bax/Bcl2 ratio was significantly increase in HepG2 and <br/>significantly decreased in THLE2 cells. P21 gene showed a significantly <br/>increase in both cell lines, however, the increase in HepG2 was more <br/>remarkable. Meanwhile, the expression levels of the genes responsible for <br/>angiogenesis and tumor progression, vascular permeability factor and matrix <br/>metalloproteinase-9, were significantly decreased in HepG2 cells and <br/>significantly increased in THLE2 cells. In conclusion, the obtained results <br/>suggest a potential selective toxic effect of pomegranate peel extract against <br/>HepG2 cell lines. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | تشخيص أكثر من %80 من مرضى سرطان الكبد بسرطان الخلايا الكبدية ، وهو مقاوم لمعظم عوامل العلاج الكيميائي التقليدية. علاوة على ذلك ، يرتبط استخدام عوامل الوقاية الكيميائية عادة˝ بالآثار الجانبية التي تؤدي إلى تدمير الأنسجة الطبيعية. لذلك ، أصبح العثور على عامل علاجي انتقائي وغير سام للخلايا<br/>الطبيعية ولا يطور مقاومة أو آثا ˝را جانبية ضاره هو الجانب الأكثر صعوبة في علاج السرطان . تبحث<br/>الدراسة الحالية في التأثيرات الانتقائية المحتملة لمضادات الأورام لمستخلص قشر الرمان من خلال<br/>دراسة تأثير المستخلص على حيوية الخلية ، وتفتيت الحمض النووي ، وتوقف دورة الخلية ، والتعبير عن الجينات المرتبطة بالسرطان في خطوط الخلايا الكبدية المسرطنة (HepG2) و الطبيعية (THLE2)<br/>للإنسان . تم تقييم الدلالات أو المؤشرات السابقة باستخدام إختبارات MTT وassay Comet و قياس<br/>التدفق الخلوي و QRt-PCR على التوالي. تم تحديد تركيزات التثبيط )الجرعات المميتة( لـ نصف عدد<br/>الخلايا (IC50) لكلا النوعين من خطوط الخلايا باستخدام اختبار MTT . تم إستخدام ربع ونصف<br/>التركيزات المميتة لنصف خطوط الخلايا المسرطنة HepG2) &½IC50 (¼IC50 لعلاج كلا النوعين من خطوط الخلايا فى جميع التقييمات التالية . ففى تقييم المذنب أظهر كلا التركيزين من مستخلص قشر الرمان تلفا˝ ملحوظا˝ فى الحمض النووى DNA لخطوط الخلايا المسرطنة تمثل فى طول الذيل ونسبة الحمض النووى فى الذيل والذيل اللحظى مقارنة ˝ بخطوط الخلايا المسرطنة غير المعالجة. على الجانب الآخر لم يسجل أى تغير ملحوظ فى سلامة الحمض النووى لخطوط الخلايا الكبدية السليمة(THLE2)<br/>المعالجة بمستخلص قشر الرمان وغير المعالجة .تم تسجيل الملاحظات نفسها في نتائج قياس التدفق<br/>الخلوي. وجدنا أن كلا التركيزين لمستخلص القشر تسبب فى توقف دورة الخلية في مرحلتي G1 / G0 و<br/>S في HepG2 وليس هناك تأثير فى .THLE2 أظهر إختبار PCR Rtالكمي أن كلا التركيزين<br/>لمستخلص القشر أدى إلى انخفاض كبير في مستويات التعبير الجينى لجينات COX2 ، BCL2،<br/>VEGF ، MMP9 ، CyclinB1 ، Cdk1 بينما مستويات التعبير الجينى عن Bax، P21 قد إرتفعت<br/>بشكل ملحوظ . تأثرت مستويات التعبير عن الجينات المعنية في كلا الخطين من الخلايا ، ومع ذلك ، كان<br/>التأثير أكثر وضوحا˝ في خطوط الخلايا المسرطنة .HepG2 في الختام ، تشير النتائج التي تم الحصول<br/>عليها إلى تأثير إنتقائى محتمل مضاد للأورام لمستخلص قشر الرمان ضد خطوط الخلايا المسرطنة<br/>.HepG2 |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cancer cells |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | الخلايا السرطانية |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Pomegranate extract |
| -- | antitumorigenic |
| -- | Cancer |
| -- | MTT |
| -- | Comet |
| -- | Cell cycle arrest |
| -- | Gene expression |
| -- | مستخلص الرمان |
| -- | مضاد للأورام |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Aliaa Mahmoud Issa |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wesam Taha Basal |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Neima koutb El-Senous |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2024 |
| Supervisory body | Aliaa Mahmoud Issa |
| -- | Wesam Taha Basal |
| -- | Neima Koutb El-Senousy |
| Universities | Cairo University |
| Faculties | Faculty of Science |
| Department | Department of Zoology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 22.12.2025 | 92894 | Cai01.12.21.M.Sc.2025.Me.E | 01010110092894000 | 22.12.2025 | 22.12.2025 | Thesis |